
Moxetumomab pasudotox is a nonchemotherapeutic drug that could become the standard of care for patients with relapsed/refractory hairy cell leukemia.
Moxetumomab pasudotox is a nonchemotherapeutic drug that could become the standard of care for patients with relapsed/refractory hairy cell leukemia.
Prior treatment with sorafenib followed by pembrolizumab (Keytruda) shows promising progression-free survival and overall survival in patients with advanced hepatocellular carcinoma.
Nivolumab (Opdivo) alone and in combination with ipilimumab (Yervoy) induced responses in patients with heavily pretreated gastrointestinal stromal tumors.
The addition of ramucirumab did not improve overall survival in patients with HER2-negative gastric cancer.
Published: June 12th 2025 | Updated: June 16th 2025
Published: June 10th 2025 | Updated: June 12th 2025
Published: June 2nd 2025 | Updated: June 11th 2025
Published: June 3rd 2025 | Updated: June 11th 2025
Published: May 30th 2025 | Updated: June 5th 2025
Published: April 18th 2025 | Updated: April 21st 2025